# Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

> **NCT00003512** · PHASE2 · WITHDRAWN · sponsor: **Burzynski Research Institute**

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003512
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1999-02-18
- **Primary completion:** 2000-04-26
- **Final completion:** 2000-04-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants enrolled
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003512, "Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00003512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*